BioMarin Completes Acquisition of Inozyme Pharma
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has successfully completed its acquisition of Inozyme Pharma, Inc. (NASDAQ: INZY) for $4.00 per share in an all-cash transaction valued at approximately $270 million. This strategic acquisition reinforces BioMarin's commitment to expanding its enzyme therapies portfolio with the addition of INZ-701, a late-stage enzyme replacement therapy currently in development to treat ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency. ENPP1 Deficiency is a rare genetic disorder that leads to serious complications affecting blood vessels, soft tissues, and bone health.
Details of the Acquisition
The acquisition agreement was initiated with a definitive merger agreement announced earlier. BioMarin's tender offer commenced on June 2, and concluded just one minute after 11:59 p.m. EDT on June 30, where an impressive 70% of Inozyme's outstanding shares were tendered. Following this successful tender offer, the merger was executed as planned, resulting in all remaining shares converting to cash at the same rate as offered in the tender.
Post-Acquisition Steps
After the merger's completion, the shares of Inozyme were delisted from the Nasdaq Global Select Market, signifying the full integration of the two companies. This merger not only cements BioMarin's position in the biotechnology industry but also enhances treatment options for patients facing the challenges of ENPP1 Deficiency.
Expert Guidance in the Transaction
In completing this acquisition, BioMarin received exclusive financial advice from Goldman Sachs & Co. LLC, while Cooley LLP provided legal counsel. For Inozyme, Centerview Partners LLC acted as financial advisor, and Goodwin Procter LLP and WilmerHale LLP offered legal services throughout the process. This collaborative effort ensured a smooth transition during the acquisition.
About BioMarin Pharmaceutical Inc.
BioMarin is a leading biotechnology company dedicated to turning genetic discoveries into life-changing medicines for patients. Established in 1997, the company is based in San Rafael, California. With a solid lineup of eight commercial therapies and a robust pipeline of clinical and preclinical products, BioMarin focuses on leveraging genetic science to develop innovative treatments for genetically defined conditions worldwide.
About Inozyme Pharma
Inozyme Pharma is a biotechnology firm in the clinical stage, specializing in therapeutics that engage the PPi-Adenosine Pathway, a crucial component for blood vessel and bone health. With a team of around 50 professionals in Boston, they are dedicated to developing INZ-701, an enzyme replacement therapy that targets ENPP1 Deficiency.
Frequently Asked Questions
1. What is the significance of the BioMarin and Inozyme acquisition?
The acquisition enhances BioMarin's enzyme therapies portfolio, introducing a new treatment option for patients with ENPP1 Deficiency.
2. How much did BioMarin pay for Inozyme?
BioMarin acquired Inozyme for $4.00 per share, totaling approximately $270 million.
3. What therapy is included in this acquisition?
The acquisition includes INZ-701, a late-stage enzyme replacement therapy developed for ENPP1 Deficiency.
4. When did BioMarin's tender offer take place?
The tender offer started on June 2 and expired on June 30, resulting in a successful acceptance of tendered shares.
5. Who provided financial advisory services during this acquisition?
Goldman Sachs & Co. LLC served as the exclusive financial advisor to BioMarin during the acquisition process.
